C4X Discovery links with PhoreMost to accelerate Parkinson's pipeline

UK-based C4X Discovery Holdings (AIM: C4XD) saw its shares climb 4.55% to 52.80 pence, after announcing a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s disease, will combine both companies’ technology platforms.

The addition of PhoreMost’s SITESEEKER screening platform will bolster the C4XD drug discovery pipeline by validating novel targets already identified by C4XD’s proprietary target identification platform, Taxonomy3, and provide chemical starting points to launch drug discovery programs.

“As part of our strategy to become the world’s most productive drug discovery company, we continually assess cutting edge technologies that add to our current capabilities in target identification and drug design. PhoreMost has one such technology with the potential to both validate targets and provide chemistry starting points for our molecular design platforms. This partnership complements C4XD’s existing target validation collaborations and enables us to accelerate our portfolio growth whilst decreasing the timelines in drug discovery,” commented C4X chief executive Dr Clive Dix.